API Gallery
The Erythromycin Thiocyanate market is expected to grow at a CAGR of 6.2% from 2024 to 2032, driven by its broad-spectrum antibacterial activity and rising demand in human and veterinary medicine.
The Erythrosine B market is expected to grow at a CAGR of 5.8% from 2024 to 2032, driven by its widespread application as a synthetic red dye in the food, pharmaceutical, and cosmetic industries.
The Esaxerenone market is projected to grow at a CAGR of 7.1% from 2024 to 2032, driven by the rising global prevalence of hypertension and chronic kidney disease (CKD), particularly among aging populations.
The Escin market is expected to grow at a CAGR of 5.4% from 2024 to 2032, driven by its increasing use in the treatment of chronic venous insufficiency (CVI), edema, and as an anti-inflammatory agent in both pharmaceutical and cosmetic products.
The Escitalopram Oxalate market is projected to grow at a CAGR of 4.9% from 2024 to 2032, driven by its widespread use in the treatment of depression, anxiety disorders, and other mood-related conditions.
The Esculin market is projected to grow at a CAGR of 5.1% from 2024 to 2031, driven by its growing use in the treatment of venous disorders such as chronic venous insufficiency, varicose veins, and hemorrhoids.
The Esketamine Hydrochloride market is projected to grow at a CAGR of 9.2% from 2024 to 2032, driven by its increasing adoption in the treatment of depression, particularly treatment-resistant depression, and its expanding use in mental health therapies.
The Eslicarbazepine Acetate market is projected to grow at a CAGR of 7.4% from 2025 to 2035, driven by its increasing use in the treatment of partial-onset seizures in epilepsy and its growing application as a monotherapy.
Esomeprazole Magnesium API is a widely prescribed active pharmaceutical ingredient used in the management of acid-related gastrointestinal conditions, including gastroesophageal reflux disease (GERD), peptic ulcers, and erosive esophagitis.
Acoltremon API market is projected to witness robust growth, expanding at a CAGR of 6.8% during the forecast period from 2025 to 2035.
Atrasentan Market is experiencing a CAGR of 6.2% during the forecast period from 2025-2035.
Datopotamab deruxtecan-dlnk (Dato-DXd) (HBA) market is experiencing a CAGR of 8.8% during the forecast period, driven by growing demand for precision oncology therapies and advancements in antibody-drug conjugate (ADC) technology.
Fitusiran market is experiencing a CAGR of 7.0% during the forecast period, driven by the rising prevalence of hemophilia and related bleeding disorders worldwide.
Gepotidacin API market is experiencing a CAGR of 8% during the forecast period from 2025-2035.
Mirdametinib API market is experiencing a CAGR of 7.8% during the forecast period from 2025-2035, driven by increasing clinical trials and growing demand for precision therapies.
Search from 10,000 + API reports
How can we help you?
Reach out to discuss how our team can help your business achieve real results.
